Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512666 | 0.94 | MAPT (0.53) | MAPTALDH1A1LMNAP2RX3TRPV1 | |
| SCHEMBL3867002 | 0.80 | LMNA (0.56) | MAPTALDH1A1LMNANPC1MAPK1 | |
| SCHEMBL6096546 | 0.79 | ALDH1A1 (0.53) | MAPTALDH1A1LMNAP2RX3PARP1 | |
| SCHEMBL29826209 | 0.78 | TRPV1 (0.49) | TRPV1FAAHPARP1TNKS2PARP2 | |
| SCHEMBL1845995 | 0.78 | CTSK (0.51) | MAPTLMNATRPV1PARP1TNKS2 | |
| SCHEMBL6474214 | 0.78 | LMNA (0.60) | MAPTLMNATRPV1FAAHBAZ2B | |
| SCHEMBL21588274 | 0.78 | TRPV1 (0.48) | TRPV1FAAHPARP1TNKS2PARP2 | |
| SCHEMBL21154244 | 0.78 | CFTR (0.56) | MAPTLMNAPARP1TNKS2PARP2 | |
| SCHEMBL1841280 | 0.78 | LMNA (0.46) | MAPTLMNATRPV1PARP1TNKS2 | |
| SCHEMBL5510072 | 0.78 | F12 (0.47) | MAPTLMNAPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-07-06 | — | — | US | disclosed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | ROBICHAUD ALBERT J (US) | 2004-02-19 | — | — | US | disclosed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | MAPT 4115/4885ALDH1A1 704/4885LMNA 1683/4885 |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | MAPT 4230/4885ALDH1A1 1399/4885LMNA 1208/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | MAPT 4115/4885ALDH1A1 704/4885LMNA 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.